ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Enliven Therapeutics Inc

Enliven Therapeutics Inc (ELVN)

27,63
-0,22
(-0,79%)
Geschlossen 02 November 9:00PM
27,63
-0,04
(-0,14%)
Nach Börsenschluss: 12:18AM

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
27,63
Gebot
15,00
Fragen
47,13
Volumen
432.979
26,91 Tagesbereich 28,375
9,80 52-Wochen-Bereich 30,03
Marktkapitalisierung
Handelsende
27,85
Handelsbeginn
28,19
Letzte Trade
1
@
29.02
Letzter Handelszeitpunkt
Finanzvolumen
US$ 11.935.056
VWAP
27,565
Durchschnittliches Volumen (3 Mio.)
226.865
Ausgegebene Aktien
47.237.207
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-4,17
Gewinn pro Aktie (EPS)
-1,52
Erlöse
-
Nettogewinn
-71,58M

Über Enliven Therapeutics Inc

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Enliven Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ELVN. The last closing price for Enliven Therapeutics was US$27,85. Over the last year, Enliven Therapeutics shares have traded in a share price range of US$ 9,80 to US$ 30,03.

Enliven Therapeutics currently has 47.237.207 shares in issue. The market capitalisation of Enliven Therapeutics is US$1,32 billion. Enliven Therapeutics has a price to earnings ratio (PE ratio) of -4.17.

ELVN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1.73-5.8923705722129.3629.6927.6317728028.37186878CS
41.515.7810107197526.1230.0325.4822252328.20567753CS
125.9827.621247113221.6530.0320.82522686525.23862329CS
269.9556.27828054317.6830.0317.6825355124.04133875CS
5215.48127.40740740712.1530.039.823178720.7178175CS
1563.4314.17355371924.230.039.819898020.27094372CS
2603.4314.17355371924.230.039.819898020.27094372CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
VSTEVast Renewable Ltd
US$ 4,98
(149,00%)
68,54M
INVZWInnoviz Technologies Ltd
US$ 0,096
(96,71%)
22,71k
CDXCChromaDex Corporation
US$ 5,87
(68,19%)
37,88M
ATHAAthira Pharma Inc
US$ 0,606
(41,56%)
239,63M
TILEInterface Inc
US$ 23,24
(33,03%)
2,16M
EPIXESSA Pharma Inc
US$ 1,45
(-72,12%)
34,3M
ELABElevai Labs Inc
US$ 0,0288
(-51,19%)
202,28M
OSTOstin Technology Group Company Ltd
US$ 0,275
(-45,00%)
2,27M
LXRXLexicon Pharmaceuticals Inc
US$ 1,23
(-36,92%)
21M
VCIGVCI Global Ltd
US$ 0,0583
(-27,58%)
26,57M
ATHAAthira Pharma Inc
US$ 0,606
(41,56%)
239,63M
SQQQProShares UltraPro Short QQQ
US$ 7,44
(-2,11%)
216,16M
NVDANVIDIA Corporation
US$ 135,40
(1,99%)
209,27M
ELABElevai Labs Inc
US$ 0,0288
(-51,19%)
202,28M
INTCIntel Corporation
US$ 23,20
(7,81%)
173,47M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock